MA49061A - Dérivés 4-sulfonylaminocarbonylquinoline pour augmenter l'activité cftr - Google Patents
Dérivés 4-sulfonylaminocarbonylquinoline pour augmenter l'activité cftrInfo
- Publication number
- MA49061A MA49061A MA049061A MA49061A MA49061A MA 49061 A MA49061 A MA 49061A MA 049061 A MA049061 A MA 049061A MA 49061 A MA49061 A MA 49061A MA 49061 A MA49061 A MA 49061A
- Authority
- MA
- Morocco
- Prior art keywords
- sulfonylaminocarbonylquinoline
- derivatives
- cftr activity
- increase cftr
- increase
- Prior art date
Links
- OEJDKEBUAWWPGJ-UHFFFAOYSA-N S(=O)(=O)=NC(=O)C1=CC=NC2=CC=CC=C12 Chemical class S(=O)(=O)=NC(=O)C1=CC=NC2=CC=CC=C12 OEJDKEBUAWWPGJ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762491433P | 2017-04-28 | 2017-04-28 | |
| US201762569212P | 2017-10-06 | 2017-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49061A true MA49061A (fr) | 2021-04-21 |
Family
ID=62165726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049061A MA49061A (fr) | 2017-04-28 | 2018-04-30 | Dérivés 4-sulfonylaminocarbonylquinoline pour augmenter l'activité cftr |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20200055844A1 (fr) |
| EP (1) | EP3615528B1 (fr) |
| CA (1) | CA3061476A1 (fr) |
| MA (1) | MA49061A (fr) |
| WO (1) | WO2018201126A1 (fr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202140422A (zh) | 2014-10-06 | 2021-11-01 | 美商維泰克斯製藥公司 | 囊腫纖維化症跨膜傳導調節蛋白之調節劑 |
| SG11201802798WA (en) | 2015-10-06 | 2018-05-30 | Proteostasis Therapeutics Inc | Compounds, compositions, and methods for modulating cftr |
| GEP20217329B (en) | 2016-09-30 | 2021-12-10 | Vertex Pharma | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| EA202192783A1 (ru) | 2016-12-09 | 2022-02-24 | Вертекс Фармасьютикалз Инкорпорейтед | Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора |
| MA54105A (fr) | 2017-06-08 | 2021-09-15 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
| IL272032B2 (en) | 2017-07-17 | 2026-04-01 | Vertex Pharma | Combination therapy for the treatment of cystic fibrosis including N-(1,3-DIMETHYLPYRAZOL-4-YL)SULFONYL-6-[3-(3,3,3-TRIFLUORO-2,2- DIMETHYL-PROPOXY)PYRAZOL-1-YL]-2-[(4S)-2,2,4- TRIMETHYLPYRROLIDIN-1-YL]PYRIDINE-3-CARBOXAMIDE and |
| MA49752A (fr) | 2017-08-02 | 2021-04-21 | Vertex Pharma | Procédés de préparation de composés de pyrrolidine |
| CA3078893A1 (fr) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Formes cristallines et compositions de modulateurs de cftr |
| KR102716244B1 (ko) | 2017-12-08 | 2024-10-14 | 버텍스 파마슈티칼스 인코포레이티드 | 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법 |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| RS64018B1 (sr) | 2018-02-15 | 2023-03-31 | Vertex Pharma | Makrocikli kao modulatori transmembranskog regulatora provodnosti cistične fibroze, njihove farmaceutske kompozicije, njihova upotreba u lečenju cistične fibroze i proces njihove izrade |
| WO2019200246A1 (fr) | 2018-04-13 | 2019-10-17 | Alexander Russell Abela | Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur |
| WO2020006269A1 (fr) | 2018-06-27 | 2020-01-02 | Proteostasis Therapeutics, Inc. | Composés améliorant l'activité du protéasome |
| IT201900000687A1 (it) * | 2019-01-16 | 2020-07-16 | Fondazione St Italiano Tecnologia | Composti e composizioni per il trattamento della fibrosi cistica |
| TWI848092B (zh) | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| US11873300B2 (en) | 2019-08-14 | 2024-01-16 | Vertex Pharmaceuticals Incorporated | Crystalline forms of CFTR modulators |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| WO2022036060A1 (fr) | 2020-08-13 | 2022-02-17 | Vertex Pharmaceuticals Incorporated | Formes cristallines de modulateurs de cftr |
| US12612416B2 (en) | 2020-10-07 | 2026-04-28 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| MX2023006770A (es) | 2020-12-10 | 2023-08-14 | Vertex Pharma | Metodos de tratamiento para fibrosis quistica. |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4336264A (en) | 1980-06-19 | 1982-06-22 | Eli Lilly And Company | 1-Benzoyl-3-(isoxazolyl or benzisoxazolyl)-ureas and insecticidal use thereof |
| WO2008046072A2 (fr) | 2006-10-13 | 2008-04-17 | The Board Of Regents Of The University Of Texas System | Inducteurs chimiques de la neurogénèse |
| US8193225B2 (en) | 2006-10-13 | 2012-06-05 | The Board Of Regents Of The University Of Texas System | Isoxazole amides, derivatives and methods of chemical induction of neurogenesis |
| US8569899B2 (en) | 2009-12-30 | 2013-10-29 | Stmicroelectronics, Inc. | Device and method for alignment of vertically stacked wafers and die |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| JP6165733B2 (ja) | 2011-09-16 | 2017-07-19 | ノバルティス アーゲー | Ｎ−置換ヘテロシクリルカルボキサミド類 |
| CN103946221B (zh) | 2011-09-16 | 2016-08-03 | 诺华股份有限公司 | 用于治疗囊性纤维化的杂环化合物 |
| AU2013319788B2 (en) | 2012-09-24 | 2019-04-11 | Yissum Reasearch Development Company of the Hebrew University Of Jerusalem Ltd. | Restoration of the CFTR function by splicing modulation |
| US9676779B2 (en) | 2012-11-20 | 2017-06-13 | Discoverybiomed, Inc. | Small molecule CFTR correctors |
| CA2891965A1 (fr) | 2012-11-20 | 2014-05-30 | Discoverybiomed, Inc. | Correcteurs de cftr bicycliques et tricycliques a petites molecules |
| EP2968323A4 (fr) | 2013-03-13 | 2016-12-14 | Flatley Discovery Lab | Composés de pyridazinone et procédés pour le traitement de fibrose kystique |
| EP2968285A4 (fr) | 2013-03-13 | 2016-12-21 | Flatley Discovery Lab | Composés et procédés pour le traitement de fibrose kystique |
| CA2903103C (fr) | 2013-03-15 | 2020-06-09 | Discoverybiomed, Inc. | Derives de coumarine et leurs methodes d'utilisation dans le traitement de la fibrose kystique, de la bronchopneumopathie chronique obstructive et des troubles lies a des proteine s mal repliees |
| EP2968987A4 (fr) | 2013-03-15 | 2017-04-26 | Vertex Pharmaceuticals Inc. | Correcteurs agissant par l'intermédiaire de msd1 de la protéine cftr |
| WO2014176553A1 (fr) | 2013-04-26 | 2014-10-30 | Vertex Pharmaceuticals Incorporated | Correcteurs agissant par le biais du domaine msd1 de la protéine cftr |
| CA3122383A1 (fr) | 2013-05-07 | 2014-11-13 | Galapagos Nv | Nouveaux composes et leurs compositions pharmaceutiques pour le traitement de la mucoviscidose. |
| SG11201802798WA (en) * | 2015-10-06 | 2018-05-30 | Proteostasis Therapeutics Inc | Compounds, compositions, and methods for modulating cftr |
-
2018
- 2018-04-30 CA CA3061476A patent/CA3061476A1/fr active Pending
- 2018-04-30 WO PCT/US2018/030123 patent/WO2018201126A1/fr not_active Ceased
- 2018-04-30 EP EP18724750.7A patent/EP3615528B1/fr active Active
- 2018-04-30 US US16/609,076 patent/US20200055844A1/en not_active Abandoned
- 2018-04-30 MA MA049061A patent/MA49061A/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20200055844A1 (en) | 2020-02-20 |
| WO2018201126A1 (fr) | 2018-11-01 |
| EP3615528A1 (fr) | 2020-03-04 |
| EP3615528B1 (fr) | 2022-02-16 |
| CA3061476A1 (fr) | 2018-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45397A (fr) | Composés, compositions et procédés pour augmenter l'activité du cftr | |
| MA41253A (fr) | Composés, compositions et procédés pour augmenter l'activité du cftr | |
| EP3717479C0 (fr) | Dérivés de thiazole microbiocides | |
| DK3887360T3 (da) | Mikrobiocide thiazolderivater | |
| MA42488A (fr) | Composés, compositions et procédés pour augmenter l'activité du cftr | |
| EP3431075A4 (fr) | Forme galénique d'édaravone | |
| EP3442488A4 (fr) | Compositions pour l'application topique de composés | |
| EP3500672A4 (fr) | Banques d'acides nucléiques synthétisés de novo | |
| IL283445A (en) | Jettable composition | |
| EP2970119A4 (fr) | Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques | |
| EP2968137A4 (fr) | Formulations d'émulsion | |
| EP3426242A4 (fr) | Icaritine et dérivés d'icaritine | |
| MA54521A (fr) | Dérivés d'oxopyridine substitués | |
| EP3403655A4 (fr) | Composition pour augmenter l'expression de pgc-1 | |
| EP3324925A4 (fr) | Formulations topiques pour la peau | |
| EP3250230A4 (fr) | Modulateurs d'activité du complément | |
| EP3283171A4 (fr) | Dérivés d'amphotéricine b | |
| EP3684092C0 (fr) | Modèle tdm pour éviter les interférences intra-ue | |
| EP4045163A4 (fr) | Boîte d'activité | |
| MA49127A (fr) | Dérivés d'indole n-substitués | |
| PL3487491T3 (pl) | Kompozycje do zwiększenia aktywności mózgu | |
| EP3632451A4 (fr) | Préparation topique hydratante | |
| EP3261631A4 (fr) | Inhibition de l'activité d'olig2 | |
| EP3907185A4 (fr) | Éthanol | |
| IL271884B1 (en) | Compounds for the reducing lipotoxic damage |